MET Oncogene in Non-Small Cell Lung Cancer: Mechanism of MET Dysregulation and Agents Targeting the HGF/c-Met Axis

Immune checkpoint inhibitors for patients with advanced lung cancer and oncogenic driver alterations: results from the IMMUNOTARGET registry

(2019) J Mazières et al.   ANNALS OF ONCOLOGY

Impact of MET inhibitors on survival among patients with non-small cell lung cancer harboring MET exon 14 mutations: a retrospective analysis

(2019) Mark M. Awad et al.   LUNG CANCER

Clinicopathological implications of MET exon 14 mutations in non-small cell lung cancer – A systematic review and meta-analysis

(2018) Huy Gia Vuong et al.   LUNG CANCER

PD-L1 Expression, Tumor Mutational Burden, and Response to Immunotherapy in Patients with MET exon 14 Altered Lung Cancers

(2018) J K Sabari et al.   ANNALS OF ONCOLOGY

LBA51Analysis of resistance mechanisms to osimertinib in patients with EGFR T790M advanced NSCLC from the AURA3 study

(2018) V A Papadimitrakopoulou et al.   ANNALS OF ONCOLOGY

LBA50Mechanisms of acquired resistance to first-line osimertinib: Preliminary data from the phase III FLAURA study

(2018) S S Ramalingam et al.   ANNALS OF ONCOLOGY

Phase II randomised discontinuation trial of cabozantinib in patients with advanced solid tumours

(2017) Patrick Schöffski et al.   EUROPEAN JOURNAL OF CANCER

Results From the Phase III Randomized Trial of Onartuzumab Plus Erlotinib Versus Erlotinib in Previously Treated Stage IIIB or IV Non–Small-Cell Lung Cancer: METLung

(2017) David R. Spigel et al.   JOURNAL OF CLINICAL ONCOLOGY

Responses to Crizotinib Can Occur in High-Level MET -Amplified Non–Small Cell Lung Cancer Independent of MET Exon 14 Alterations

(2017) Rafael Caparica et al.   Journal of Thoracic Oncology

Targeting MET in Lung Cancer: Will Expectations Finally Be MET?

(2017) Alexander Drilon et al.   Journal of Thoracic Oncology

Phase I Results from a Study of Crizotinib in Combination with Erlotinib in Patients with Advanced Nonsquamous Non–Small Cell Lung Cancer

(2017) Sai-Hong Ignatius Ou et al.   Journal of Thoracic Oncology

MET Exon 14 Skipping Mutations in Lung Adenocarcinoma: Clinicopathologic Implications and Prognostic Values

(2017) Geun Dong Lee et al.   Journal of Thoracic Oncology

MET exon 14 skipping mutation in triple-negative pulmonary adenocarcinomas and pleomorphic carcinomas: An analysis of intratumoral MET status heterogeneity and clinicopathological characteristics

(2017) Dohee Kwon et al.   LUNG CANCER

Characterization of In Vivo Resistance to Osimertinib and JNJ-61186372, an EGFR/Met Bispecific Antibody, Reveals Unique and Consensus Mechanisms of Resistance

(2017) Kristina B. Emdal et al.   MOLECULAR CANCER THERAPEUTICS

A phase I study of foretinib plus erlotinib in patients with previously treated advanced non-small cell lung cancer: Canadian cancer trials group IND.196

(2017) Natasha B. Leighl et al.   Oncotarget

MET exon 14 mutations as targets in routine molecular analysis of primary sarcomatoid carcinoma of the lung

(2017) Raphaël Saffroy et al.   Oncotarget

Ror2 signaling regulates Golgi structure and transport through IFT20 for tumor invasiveness

(2017) Michiru Nishita et al.   Scientific Reports

ABBV-399, a c-Met Antibody–Drug Conjugate that Targets Both MET –Amplified and c-Met–Overexpressing Tumors, Irrespective of MET Pathway Dependence

(2016) Jieyi Wang et al.   CLINICAL CANCER RESEARCH

MET Amplification and Exon 14 Splice Site Mutation Define Unique Molecular Subgroups of Non-Small Cell Lung Carcinoma with Poor Prognosis

(2016) J. H. Tong et al.   CLINICAL CANCER RESEARCH

MET Exon 14 Mutations in Non–Small-Cell Lung Cancer Are Associated With Advanced Age and Stage-Dependent MET Genomic Amplification and c-Met Overexpression

(2016) Mark M. Awad et al.   JOURNAL OF CLINICAL ONCOLOGY

Next-Generation Sequencing of Pulmonary Sarcomatoid Carcinoma Reveals High Frequency of Actionable MET Gene Mutations

(2016) Xuewen Liu et al.   JOURNAL OF CLINICAL ONCOLOGY

Identifying the Appropriate FISH Criteria for Defining MET Copy Number–Driven Lung Adenocarcinoma through Oncogene Overlap Analysis

(2016) Sinéad A. Noonan et al.   Journal of Thoracic Oncology

Combined Pan-HER and ALK/ROS1/MET Inhibition with Dacomitinib and Crizotinib in Advanced Non–Small Cell Lung Cancer: Results of a Phase I Study

(2016) Pasi A. Jänne et al.   Journal of Thoracic Oncology

Response to Crizotinib Observed in Lung Adenocarcinoma with MET Copy Number Gain but without a High-Level MET/CEP7 Ratio, MET Overexpression, or Exon 14 Splicing Mutations

(2016) Yan Zhang et al.   Journal of Thoracic Oncology

A Randomized Phase 2 Study Comparing the Combination of Ficlatuzumab and Gefitinib with Gefitinib Alone in Asian Patients with Advanced Stage Pulmonary Adenocarcinoma

(2016) Tony Shu Kam Mok et al.   Journal of Thoracic Oncology

The Unique Characteristics of MET Exon 14 Mutation in Chinese Patients with NSCLC

(2016) Si-Yang Liu et al.   Journal of Thoracic Oncology

Characterization of 298 Patients with Lung Cancer Harboring MET Exon 14 Skipping Alterations

(2016) Alexa B. Schrock et al.   Journal of Thoracic Oncology

Scientific Advances in Lung Cancer 2015

(2016) Anne S. Tsao et al.   Journal of Thoracic Oncology

Erlotinib, cabozantinib, or erlotinib plus cabozantinib as second-line or third-line treatment of patients with EGFR wild-type advanced non-small-cell lung cancer (ECOG-ACRIN 1512): a randomised, controlled, open-label, multicentre, phase 2 trial

(2016) Joel W Neal et al.   LANCET ONCOLOGY

MET Exon 14 Skipping in Non-Small Cell Lung Cancer

(2016) Rebecca S. Heist et al.   ONCOLOGIST

Benefit-Risk Summary of Crizotinib for the Treatment of Patients With ROS1 Alteration-Positive, Metastatic Non-Small Cell Lung Cancer

(2016) D. Kazandjian et al.   ONCOLOGIST

MET-Driven Resistance to Dual EGFR and BRAF Blockade May Be Overcome by Switching from EGFR to MET Inhibition in BRAF-Mutated Colorectal Cancer

(2016) F. Pietrantonio et al.   Cancer Discovery

The Efficacy and Risk Profile of c-Met inhibitors in Non-small Cell Lung Cancer: a Meta-analysis

(2016) Sa Ye et al.   Scientific Reports

A randomized, double-blind, placebo-controlled, phase III trial of erlotinib with or without a c-Met inhibitor tivantinib (ARQ 197) in Asian patients with previously treated stage IIIB/IV nonsquamous nonsmall-cell lung cancer harboring wild-type epidermal growth factor receptor (ATTENTION study)

(2015) H. Yoshioka et al.   ANNALS OF ONCOLOGY

Response to Crizotinib in a Patient With Lung Adenocarcinoma Harboring a MET Splice Site Mutation

(2015) Russell W. Jenkins et al.   Clinical Lung Cancer

Phase III Multinational, Randomized, Double-Blind, Placebo-Controlled Study of Tivantinib (ARQ 197) Plus Erlotinib Versus Erlotinib Alone in Previously Treated Patients With Locally Advanced or Metastatic Nonsquamous Non–Small-Cell Lung Cancer

(2015) Giorgio Scagliotti et al.   JOURNAL OF CLINICAL ONCOLOGY

MET-Mutated NSCLC with Major Response to Crizotinib

(2015) Melody A. Mendenhall et al.   Journal of Thoracic Oncology

MET Mutation Associated with Responsiveness to Crizotinib

(2015) Saiama N. Waqar et al.   Journal of Thoracic Oncology

MET 14 Deletion in Sarcomatoid Non-Small-Cell Lung Cancer Detected by Next-Generation Sequencing and Successfully Treated with a MET Inhibitor

(2015) Carrie Lee et al.   Journal of Thoracic Oncology

Activating MET kinase rearrangements in melanoma and Spitz tumours

(2015) Iwei Yeh et al.   Nature Communications

Response to MET Inhibitors in Patients with Stage IV Lung Adenocarcinomas Harboring MET Mutations Causing Exon 14 Skipping

(2015) P. K. Paik et al.   Cancer Discovery

Activation of MET via Diverse Exon 14 Splicing Alterations Occurs in Multiple Tumor Types and Confers Clinical Sensitivity to MET Inhibitors

(2015) G. M. Frampton et al.   Cancer Discovery

Unknown

(2015)   Oncotarget

U.S. Food and Drug Administration Approval: Crizotinib for Treatment of Advanced or Metastatic Non-Small Cell Lung Cancer That Is Anaplastic Lymphoma Kinase Positive

(2014) S. M. Malik et al.   CLINICAL CANCER RESEARCH

Discovery of (S)-1-(1-(Imidazo[1,2-a]pyridin-6-yl)ethyl)-6-(1-methyl-1H-pyrazol-4-yl)-1H-[1,2,3]triazolo[4,5-b]pyrazine (Volitinib) as a Highly Potent and Selective Mesenchymal–Epithelial Transition Factor (c-Met) Inhibitor in Clinical Development for Treatment of Cancer

(2014) Hong Jia et al.   JOURNAL OF MEDICINAL CHEMISTRY

Comprehensive molecular profiling of lung adenocarcinoma

(2014) Eric A. Collisson et al.   NATURE

Anchored multiplex PCR for targeted next-generation sequencing

(2014) Zongli Zheng et al.   NATURE MEDICINE

MET Gene Copy Number Predicts Worse Overall Survival in Patients with Non-Small Cell Lung Cancer (NSCLC); A Systematic Review and Meta-Analysis

(2014) Anastasios Dimou et al.   PLoS One

The landscape of kinase fusions in cancer

(2014) Nicolas Stransky et al.   Nature Communications

Targeting MET Amplification as a New Oncogenic Driver

(2014) Hisato Kawakami et al.   Cancers

The emerging role of MET/HGF inhibitors in oncology

(2013) Giorgio V. Scagliotti et al.   CANCER TREATMENT REVIEWS

EMD 1214063 and EMD 1204831 Constitute a New Class of Potent and Highly Selective c-Met Inhibitors

(2013) F. Bladt et al.   CLINICAL CANCER RESEARCH

MET As a Possible Target for Non–Small-Cell Lung Cancer

(2013) Ahad A. Sadiq et al.   JOURNAL OF CLINICAL ONCOLOGY

Randomized Phase II Trial of Onartuzumab in Combination With Erlotinib in Patients With Advanced Non–Small-Cell Lung Cancer

(2013) David R. Spigel et al.   JOURNAL OF CLINICAL ONCOLOGY

An ‘in-cell trial’ to assess the efficacy of a monovalent anti-MET antibody as monotherapy and in association with standard cytotoxics

(2013) Silvia Benvenuti et al.   Molecular Oncology

Monovalent antibody design and mechanism of action of onartuzumab, a MET antagonist with anti-tumor activity as a therapeutic agent

(2013) M. Merchant et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Amplification of the MET Receptor Drives Resistance to Anti-EGFR Therapies in Colorectal Cancer

(2013) Alberto Bardelli et al.   Cancer Discovery

Rationale and Design of MARQUEE: A Phase III, Randomized, Double-Blind Study of Tivantinib Plus Erlotinib Versus Placebo Plus Erlotinib in Previously Treated Patients With Locally Advanced or Metastatic, Nonsquamous, Non–Small-Cell Lung Cancer

(2012) Giorgio V. Scagliotti et al.   Clinical Lung Cancer

Treatment Rationale Study Design for the MetLung Trial: A Randomized, Double-Blind Phase III Study of Onartuzumab (MetMAb) in Combination With Erlotinib Versus Erlotinib Alone in Patients Who Have Received Standard Chemotherapy for Stage IIIB or IV Met-Positive Non–Small-Cell Lung Cancer

(2012) David R. Spigel et al.   Clinical Lung Cancer

The transcriptional landscape and mutational profile of lung adenocarcinoma

(2012) J.-S. Seo et al.   GENOME RESEARCH

Targeting the Hepatocyte Growth Factor–cMET Axis in Cancer Therapy

(2012) George R. Blumenschein et al.   JOURNAL OF CLINICAL ONCOLOGY

MET and Phosphorylated MET as Potential Biomarkers in Lung Cancer

(2012) Maria Tretiakova et al.   JOURNAL OF ENVIRONMENTAL PATHOLOGY TOXICOLOGY AND ONCOLOGY

Autocrine activation of the MET receptor tyrosine kinase in acute myeloid leukemia

(2012) Alex Kentsis et al.   NATURE MEDICINE

MET: a promising anticancer therapeutic target

(2012) Solange Peters et al.   Nature Reviews Clinical Oncology

A Novel Kinase Inhibitor, INCB28060, Blocks c-MET-Dependent Signaling, Neoplastic Activities, and Cross-Talk with EGFR and HER-3

(2011) X. Liu et al.   CLINICAL CANCER RESEARCH

Mechanisms of Resistance to EGFR TKIs and Development of a New Generation of Drugs in Non-Small-Cell Lung Cancer

(2011) Takayuki Kosaka et al.   JOURNAL OF BIOMEDICINE AND BIOTECHNOLOGY

MET Signaling Pathway: A Rational Target for Cancer Therapy

(2011) Leonard J. Appleman   JOURNAL OF CLINICAL ONCOLOGY

Randomized Phase II Study of Erlotinib Plus Tivantinib Versus Erlotinib Plus Placebo in Previously Treated Non–Small-Cell Lung Cancer

(2011) Lecia V. Sequist et al.   JOURNAL OF CLINICAL ONCOLOGY

Structure Based Drug Design of Crizotinib (PF-02341066), a Potent and Selective Dual Inhibitor of Mesenchymal–Epithelial Transition Factor (c-MET) Kinase and Anaplastic Lymphoma Kinase (ALK)

(2011) J. Jean Cui et al.   JOURNAL OF MEDICINAL CHEMISTRY

Activity of Crizotinib (PF02341066), a Dual Mesenchymal-Epithelial Transition (MET) and Anaplastic Lymphoma Kinase (ALK) Inhibitor, in a Non-small Cell Lung Cancer Patient with De Novo MET Amplification

(2011) Sai-Hong Ignatius Ou et al.   Journal of Thoracic Oncology

c-MET/Phospho-MET Protein Expression and MET Gene Copy Number in Non-small Cell Lung Carcinomas

(2011) Koji Tsuta et al.   Journal of Thoracic Oncology

An overview of the c-MET signaling pathway

(2011) Shawna Leslie Organ et al.   Therapeutic Advances in Medical Oncology

Preexistence and Clonal Selection of MET Amplification in EGFR Mutant NSCLC

(2010) Alexa B. Turke et al.   CANCER CELL

Activation of MET by Gene Amplification or by Splice Mutations Deleting the Juxtamembrane Domain in Primary Resected Lung Cancers

(2010) Ryoichi Onozato et al.   Journal of Thoracic Oncology

High MET Gene Copy Number Leads to Shorter Survival in Patients with Non-small Cell Lung Cancer

(2010) Heounjeong Go et al.   Journal of Thoracic Oncology

Biochemical Characterization of AMG 102: A Neutralizing, Fully Human Monoclonal Antibody to Human and Nonhuman Primate Hepatocyte Growth Factor

(2010) T. L. Burgess et al.   MOLECULAR CANCER THERAPEUTICS

MET signalling: principles and functions in development, organ regeneration and cancer

(2010) Livio Trusolino et al.   NATURE REVIEWS MOLECULAR CELL BIOLOGY

IncreasedMETGene Copy Number Negatively Affects Survival of Surgically Resected Non–Small-Cell Lung Cancer Patients

(2009) Federico Cappuzzo et al.   JOURNAL OF CLINICAL ONCOLOGY

MET Gene Copy Number in Non-small Cell Lung Cancer: Molecular Analysis in a Targeted Tyrosine Kinase Inhibitor Naïve Cohort

(2009) Michèle Beau-Faller et al.   Journal of Thoracic Oncology

Clinicopathologic and Molecular Features of Epidermal Growth Factor Receptor T790M Mutation and c-MET Amplification in Tyrosine Kinase Inhibitor-resistant Chinese Non-small Cell Lung Cancer

(2009) Hua-Jun Chen et al.   PATHOLOGY & ONCOLOGY RESEARCH

The Met tyrosine kinase receptor in development and cancer

(2008) Alessandra Gentile et al.   CANCER AND METASTASIS REVIEWS

Hepatocyte Growth Factor Induces Gefitinib Resistance of Lung Adenocarcinoma with Epidermal Growth Factor Receptor-Activating Mutations

(2008) S. Yano et al.   CANCER RESEARCH

Expression and mutational analysis ofMETin human solid cancers

(2008) Patrick C. Ma et al.   GENES CHROMOSOMES & CANCER

Chemotherapy in Addition to Supportive Care Improves Survival in Advanced Non–Small-Cell Lung Cancer: A Systematic Review and Meta-Analysis of Individual Patient Data From 16 Randomized Controlled Trials

(2008)   JOURNAL OF CLINICAL ONCOLOGY